Bristol “Dear Doctor” Letter: Abilify Shows No “Signal” For Diabetes
This article was originally published in The Pink Sheet Daily
Executive Summary
An “exhaustive review” of the aripiprazole database revealed “no increased signal for diabetes,” Bristol says in health care professionals letter explaining the new class warning for atypical antipsychotics.